Last reviewed · How we verify

Beclomethasone and Salbutamol

University of Calgary · FDA-approved active Small molecule

Beclomethasone and Salbutamol is a Combination inhaled corticosteroid and short-acting beta-2 agonist (ICS/SABA) Small molecule drug developed by University of Calgary. It is currently FDA-approved for Asthma maintenance and acute symptom relief, Chronic obstructive pulmonary disease (COPD). Also known as: Clenil Compositum.

This combination inhaler delivers a corticosteroid (beclomethasone) to reduce airway inflammation and a short-acting beta-2 agonist (salbutamol) to rapidly relieve bronchospasm.

This combination inhaler delivers a corticosteroid (beclomethasone) to reduce airway inflammation and a short-acting beta-2 agonist (salbutamol) to rapidly relieve bronchospasm. Used for Asthma maintenance and acute symptom relief, Chronic obstructive pulmonary disease (COPD).

At a glance

Generic nameBeclomethasone and Salbutamol
Also known asClenil Compositum
SponsorUniversity of Calgary
Drug classCombination inhaled corticosteroid and short-acting beta-2 agonist (ICS/SABA)
TargetGlucocorticoid receptor (beclomethasone); beta-2 adrenergic receptor (salbutamol)
ModalitySmall molecule
Therapeutic areaRespiratory / Pulmonology
PhaseFDA-approved

Mechanism of action

Beclomethasone is a topical corticosteroid that suppresses inflammatory responses in the airways by binding glucocorticoid receptors, reducing mucus production and airway edema. Salbutamol is a selective beta-2 adrenergic agonist that activates beta-2 receptors on airway smooth muscle, causing rapid bronchodilation. Together, they provide both anti-inflammatory control and acute symptom relief in asthma and COPD.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Beclomethasone and Salbutamol

What is Beclomethasone and Salbutamol?

Beclomethasone and Salbutamol is a Combination inhaled corticosteroid and short-acting beta-2 agonist (ICS/SABA) drug developed by University of Calgary, indicated for Asthma maintenance and acute symptom relief, Chronic obstructive pulmonary disease (COPD).

How does Beclomethasone and Salbutamol work?

This combination inhaler delivers a corticosteroid (beclomethasone) to reduce airway inflammation and a short-acting beta-2 agonist (salbutamol) to rapidly relieve bronchospasm.

What is Beclomethasone and Salbutamol used for?

Beclomethasone and Salbutamol is indicated for Asthma maintenance and acute symptom relief, Chronic obstructive pulmonary disease (COPD).

Who makes Beclomethasone and Salbutamol?

Beclomethasone and Salbutamol is developed and marketed by University of Calgary (see full University of Calgary pipeline at /company/university-of-calgary).

Is Beclomethasone and Salbutamol also known as anything else?

Beclomethasone and Salbutamol is also known as Clenil Compositum.

What drug class is Beclomethasone and Salbutamol in?

Beclomethasone and Salbutamol belongs to the Combination inhaled corticosteroid and short-acting beta-2 agonist (ICS/SABA) class. See all Combination inhaled corticosteroid and short-acting beta-2 agonist (ICS/SABA) drugs at /class/combination-inhaled-corticosteroid-and-short-acting-beta-2-agonist-ics-saba.

What development phase is Beclomethasone and Salbutamol in?

Beclomethasone and Salbutamol is FDA-approved (marketed).

What are the side effects of Beclomethasone and Salbutamol?

Common side effects of Beclomethasone and Salbutamol include Tremor, Headache, Palpitations, Oral candidiasis, Hoarseness, Nervousness.

What does Beclomethasone and Salbutamol target?

Beclomethasone and Salbutamol targets Glucocorticoid receptor (beclomethasone); beta-2 adrenergic receptor (salbutamol) and is a Combination inhaled corticosteroid and short-acting beta-2 agonist (ICS/SABA).

Related